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Multipotent hematopoietic progenitorle of the human placenta as a hematopoietic organ during embryonic and fetal
development. Placental samples contained two cell populations—CD34++CD45low and CD34+CD45low—that
were found in chorionic villi and in the chorioamniotic membrane. CD34++CD45low cells express many cell
surface antigens found on multipotent primitive hematopoietic progenitors and hematopoietic stem cells.
CD34++CD45low cells contained colony-forming units culture (CFU-C) with myeloid and erythroid potential in
clonogenic in vitro assays, and they generated CD56+ natural killer cells and CD19+CD20+sIgM+ B cells in
polyclonal liquid cultures. CD34+CD45low cells mostly comprised erythroid- and myeloid-committed
progenitors, while CD34− cells lacked CFU-C. The placenta-derived precursors were fetal in origin, as
demonstrated by FISH using repeat-sequence chromosome-speciﬁc probes for X and Y. The number of
CD34++CD45low cells increased with gestational age, but their density (cells per gram of tissue) peaked at
5–8 wk, decreasing more than sevenfold at the onset of the fetal phase (9 wk of gestation). In addition to
multipotent progenitors, the placenta contained myeloid- and erythroid-committed progenitors indicative
of active in situ hematopoiesis. These data suggest that the human placenta is an important hematopoietic
organ, raising the possibility of banking placental hematopoietic stem cells along with cord blood for
transplantation.
© 2008 Elsevier Inc. All rights reserved.
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Introduction
Human hematopoiesis begins at ∼16–18.5 days of development in
the yolk sac (Luckett, 1978) and is gradually replaced by sequential
intraembryonic sites, such as the aorta-gonad-mesonephros (AGM)
region and the embryonic liver (Tavian et al., 1996). Hematopoietic
progenitors expressing CD34 and CD45 are ﬁrst detected in the AGM
at day 27 (Tavian et al., 1999), quickly expand, and disappear by day
ET
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l rights reserved.40. In the current model of hematopoietic development, intraem-
bryonic hematopoietic stem cells (HSCs), presumably produced in the
AGM region, establish deﬁnitive hematopoiesis (Cumano et al., 2000).
However, the AGM region, which contains a limited number of HSCs, is
hematopoietic for only a short time, suggesting either that AGM-
derived HSCs rapidly and efﬁciently migrate to the liver or that HSCs
are being produced in another, unidentiﬁed tissue.
The presence of HSCs in the mouse placenta with potential similar
to that of bonemarrow (BM) cells was suggested some 40 years ago by
Till and McCulloch (1961) and Dancis et al. (1968). In 1979, Melchers
showed that the mouse placenta contains hematopoietic progenitors
before the fetal liver is hematopoietic (Melchers, 1979). Two groups
recently reported that the mid-gestation murine placenta is a richly
hematopoietic organ that contains high-proliferative-potential
colony-forming cells of fetal origin (Alvarez-Silva et al., 2003) and
HSCs that can reconstitute hematopoiesis in adult mice (Ottersbach
and Dzierzak, 2005). Furthermore, murine placental hematopoiesis is
present before the placental circulation is established, demonstrating
that the placenta is not only a niche but also a source of hematopoietic
cells that functions at the same time as the AGM (Corbel et al., 2007;
25A. Bárcena et al. / Developmental Biology 327 (2009) 24–33Rhodes et al., 2008; Zeigler et al., 2006). These ﬁndings strongly
support the inclusion of the placenta in our current model of site-
speciﬁc and orchestrated embryonic hematopoiesis.
The hematopoietic potential of the human placenta is currently
unknown. CD235a+ (glycophorin A) CD34−CD45− erythroblast cells,
but not CD34+CD45+ progenitors, have been identiﬁed in ﬁrst and
second trimester placentas (Challier et al., 2001, 2005). In recent
reports, a pluripotent cell population expressing markers of mesench-
ymal and embryonic stem cells was described in crude preparations of
term placental cells (Fukuchi et al., 2004; Yen et al., 2005) and in
association with the amniotic epithelium (Miki et al., 2005).
Pluripotent stem cell markers, such as SSEA-3, -4, and TRA 1-60,
1–81, have been detected in the amnion (Miki et al., 2007). The
placental mesenchymal populations display adipogenic, osteogenic,
neurogenic, hepatogenic and pancreatogenic potential (Chang et al.,
2007; Chien et al., 2006; Fukuchi et al., 2004). However, the
hematopoietic potential of these placental cell populations has not
been explored. In the present study, we searched for hematopoietic
progenitors in the human placenta by using ﬂow cytometry and
confocal microscopy. We also investigated whether the output of this
extraembryonic hematopoietic niche remains constant or changes
over time, by estimating the frequency of hematopoietic progenitors
in placentas of different gestational ages (from 5.4 to 39.5 weeks).
We then evaluated the hematopoietic potential of cells isolated by
cell sorting using in vitro hematopoietic progenitor assays.
Materials and methods
Isolation of placental hematopoietic progenitors
This study was approved by the University of California–San
Francisco Committee on Human Research. We used the basic method
that our group devised for isolating human placental cells (Fisher et
al., 1989), with a few modiﬁcations that signiﬁcantly improved the
recovery of hematopoietic cells. We added a ﬁnal enzymatic digestion
treatment of the placental cell preparations with 181 U/ml collagenase
I-A, 0.12 mg/ml DNase I, 0.70 mg/ml hyaluronidase type I-S, and 1 mg/
ml BSA in PBS at 37 °C. Digestion continued for 5–60 min until total
cellular dissociation was observed. Then the cells were centrifuged
over Nycoprep (1.077 g/ml; Greiner Bio-One, Monroe, NC) for 30 min
(25 °C) at 600 ×g. Further puriﬁcation of CD34++CD45low or CD34
+CD45low cells was achieved by staining the cell suspensions with
directly conjugated mAbs—anti-CD34-allophycocyanin (APC) (Beck-
man Coulter, Fullerton, CA) and anti-CD45-PE (Invitrogen/Caltag,
Carlsbad, CA)—and sorted using FACSDiva or a FACSAria (Becton
Dickinson, San Jose, CA).
Isolation of hematopoietic progenitors from umbilical cord blood and
fetal BM
Samples were processed immediately after being obtained, by a
method described previously (Bárcena et al., 1999). The resulting
light-density cell suspension of fetal BM or UCB was used for
phenotypic analyses, FISH, or cell-sorting experiments as described
below for placental cells. At least 3 preparations of each type were
analyzed.
Reagents
Isotype control antibodies IgG1, IgG2a, IgG2b and IgG3 were
purchased from BD Biosciences (San Jose, CA); IgMwas obtained from
Invitrogen/Pharmingen. mAbs were conjugated to FITC, PE or APC as
indicated in the ﬁgure legends. Propidium iodide (PI) (Sigma-Aldrich,
St. Louis, MO) was used at a ﬁnal concentration of 1 μg/ml to identify
dead cells. Antibodies used for cell separation and immunoﬂuores-
cence are listed, along with their manufacturers, in Supplemental
RE
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ATable 2. Cytokines, purchased from R&D Systems (Minneapolis, MN),
are listed in Supplemental Table 3.
Hematopoietic progenitor assays
To enumerate CFU-C, methylcellulose clonal cultures of sorted
CD34++CD45low and CD34+CD45low placental cells or UCBwere prepared
at a density of 5×102/35-mm plate (BD Falcon, BD Biosciences) in either
Methocult GF H4435 (StemCell Technologies, Inc., Vancouver, BC,
Canada) or SDM supplemented with the same concentration of
methylcellulose and cytokines present in Methocult (Bárcena et al.,
1996). In some experiments, two different batches of characterized FBS
(Hyclone) and one batch of FBS (Stem Cell Technologies Inc.) was added
to SDM at the concentrations indicated in the ﬁgures. Colonies con-
taining erythrocytes were scored as BFU-E after 3 weeks at 37 °C in 5%
CO2 in air. CFU-GM (colony-forming unit granulocyte-macrophage)
colonies that expressed CD14 and CD15 were identiﬁed by morphology
and ﬂow cytometry (Muench and Bárcena, 2001). CFU-mix colonies
contained both granulocyte-macrophage and erythroid progenitors.
Lymphoid- and myelo-erythroid-megakaryocyte differentiation in
liquid cultures
Sorted CD34++CD45low cells were counted, washed in PBS contain-
ing 0.5% BSA, and cultured at 5×103 to 7.5×103 cells/ml in 48-well
plates (Costar, Cambridge, MA) in the presence of SDM supplemented
with 50 ng/ml SCF, 100 ng/ml Flt-3/Flk-2 ligand (FL), 20 ng/ml
interleukin (IL)-15, 20 ng/ml IL-7+20 ng/ml GM-CSF+20 ng/ml IL-3
(lymphoid-permissive conditions (Muench and Bárcena, 2001), or the
combination of 50 ng/ml SCF, 100 ng/ml FL, 20 ng/ml IL-15, 20 ng/ml
GM-CSF, 20 ng/ml IL-3, 20 ng/ml thrombopoietin (TPO)+10 U/ml
erythropoietin (Epo) (myelo-erythroid-megakaryocyte-permissive
conditions (Muench and Bárcena, 2004)). Medium was refreshed 2×
a week by changing half the volume and adding fresh cytokines. After
21–23 days in culture at 37 °C in 5% CO2 in air, cells were harvested,
washed with PBS supplemented with 0.5% BSA, and stained with
directly conjugated mAbs before ﬂow cytometric analyses.
B-cell differentiation cultures
Non-irradiated MS-5 murine BM stromal cells (Itoh et al., 1989)
(kindly provided by K.J. Mori, Niigata University, Niigata, Japan)
were maintained in α-minimal essential medium (Invitrogen/Gibco)
supplemented with 10% characterized FBS (Hyclone), 50 μM 2-
mercaptoethanol (Sigma), 50 U/ml of penicillin G and 50 μg/ml of
streptomycin sulfate (Invitrogen). Two days before seeding of
placental progenitors, MS-5 cells were prepared at a concentration
of 104 cells/well in 48-well tissue culture plates (Becton Dickinson)
coated with 0.1% gelatin (Sigma). CD34++CD45low placental cells were
sorted as described above and cultured at a density of 5×104 cells/well
in 0.4 ml on the MS-5 feeders in Iscove modiﬁed Dulbecco medium
(Invitrogen/Gibco) supplemented with 5% FBS, 5% human AB serum
(Gemini Bio-Products, West Sacramento, CA), 50 ng/ml SCF, 100 ng/ml
FL and 20 ng/ml IL-7. The cells were cultured for 3 weeks at 37 °C in 5%
CO2 in air and were fed every week by removing half the medium and
replacing it with fresh medium and cytokines. After 3 weeks in
culture, cells were harvested using 0.05% trypsin (Invitrogen/Gibco),
washed and stained with mAbs against CD19, CD20, IgM and CD45
prior to ﬂow cytometric analyses.
Immunoﬂuorescence and ﬂow cytometry
Cell surface phenotypic analyses were performed as described
(Bárcena et al., 1993) using a two-laser FACSCalibur or LSR II cytometer
(BD Biosciences) and CellQuest (BD Biosciences) or FlowJo (Tree Star,
Inc., Ashland, OR) software.
TE
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CD34++CD45low cells were isolated by cell sorting from the placenta
of a 19-week male fetus. BM from the same conceptus was used as a
positive control. We obtained 9×103 CD34++CD45low placental cells
and 6.6×104 CD34++CD45low fetal BM cells. Cells (2×102 to 4×102)
were deposited on slides immediately after puriﬁcation, and FISH was
performed with X and Y chromosome-speciﬁc probes using methods
that we have published (Weier et al., 2005). Results were conﬁrmed by
performing identical FISH analyses on total CD45+ cells from ﬁrst and
second trimester placentas.
Immunoﬂuorescence and confocal microscopy
Freshly isolated placental tissue from 7 to 17 weeks of gestation
was ﬁxed in 3% paraformaldehyde for 90 min, and processed as
previously described (Prakobphol et al., 2006). Biopsies were imagedFig.1. Phenotypic proﬁle and fetal originof placental hematopoietic progenitors. Inpanels a and
the indicatedmAbs andPI, to identify dead cells. (a) The forward versus side-scatter proﬁle of 10
to exclude PI+ cells (not shown). Isotype-matched negative controls are included. The gates set
versus CD45-PEdot plot (I forCD34+CD45low; II for CD34++CD45low). (b) Stainingof the same cel
was performed to highlight the CD34++CD45low (red) and CD34+CD45low (green) cells. Results a
a) from placenta and from fetal BM (FBM) from the same 19-week specimenwere hybridizedw
stained with 4′,6′-diamidino-2-phenylindole (blue). Photomicrographs of the slides at 40× m
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Ausing a Leica MZ-16 confocal microscope with a DFC camera. Sections
(30 μm) of the ﬁxed/frozen tissue were stained with mAbs against
CD34 (directly conjugated to FITC; BD Pharmingen, clone 581), CD45
(Dako, clones 2B11 +PD7/26), or vimentin (Abcam Inc, Cambridge,
MA, clone SP20). The binding of antibodies that were not direct
conjugates was detected using the appropriate species-speciﬁc
secondary antibody, either rhodamine-conjugated donkey anti-
mouse IgG (Jackson ImmunoResearch Laboratories Inc, West Grove,
PA) or Alexa 594-conjugated goat anti-rabbit (Invitrogen/Molecular
Probes). As a control, some sections were stained with the secondary
antibody alone. Staining with Hoescht 33542 or TOTO-3 iodide
(Invitrogen/Molecular Probes) was used to visualize nuclei. Slides
were imaged on a Leica CTR 6500 microscope equipped with UV 488,
546 and 633 lasers when using Hoescht staining or on a Zeiss LSM 5
Pascal when using TOTO-3. Scanned images were processed using the
Leica TCS SP5 software package. Z projections were generated in
ImageJ software.b, freshly isolated light-density cell suspension froma10-weekplacentawas stainedwith
5 cells and the electronic gate used to include all hematopoietic cells. Another gatewas set
for cell sorting experiments used inpanel c and in Figs. 6 and 7 are shown in the CD34-APC
lswithmAbs againstmarkers expressed byhematopoietic progenitors.Multicolor analysis
re representative of 12 experiments. (c) Sorted CD34++CD45low cells (using gate II in panel
ith ﬂuorescent probes speciﬁc for the X (green) or Y (red) chromosomes. Cell nuclei were
agniﬁcation were taken with a Nikon E-800 microscope/camera.
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The placenta contains hematopoietic progenitors of fetal origin
Placental samples from 5.4 to 39.5 weeks of pregnancy were
analyzed for cells expressing both CD34 and CD45 hematopoietic
progenitor cell surface markers (Lansdorp et al., 1990). Initially, we
focused on these cells so that we could discriminate between the
hematopoietic population and endothelial cells with a CD34+CD45−
phenotype. Two populations with phenotypic characteristics of
hematopoietic progenitors were observed at the following frequen-
cies and ranges among the light density fraction of placental cells:
CD34+CD45low (2.86–20.91%) and CD34++CD45low (0.03–1.2%) (n=59)
(Fig. 1a). Expression of additional antigens displayed by multipotent
progenitors and HSCs was investigated (see Supplemental Table 1).
CD34++CD45low and CD34+CD45low cells were largely CD38− (Fig. 1b).
Otherwise, placental cells were phenotypically similar to the
equivalent populations found in fetal liver and BM; some expressed
HLA-DR, CD133, low levels of CD117 (c-kit), CD90 (Thy-1), and high
levels of CD31 (PECAM-1). Neither CD34++CD45low nor CD34
+CD45low cells expressed detectable levels of CD4, CD41 (Fig. 1b),
CD95 or CXCR4 (data not shown). Both populations expressed CD13
and CD33 (Fig. 5b) and CD44 (data not shown).
The low to negative expression of CD38 by placental hematopoietic
progenitors was very intriguing, since CD34++CD38− cells are con-
sidered to be highly enriched in HSC. CD38 is a type II transmembrane
glycoprotein, and an ectoenzyme (ADP-ribosyl cyclase), which
expression is upregulated during differentiation of hematopoietic
progenitors (Deaglio et al., 2001). We investigated whether the low
CD38 expression could be due to the enzymatic digestion of the
placental samples or it is intrinsic to placental tissue. Two approaches
were taken to determine the effect of enzymatic digestion on the CD38
antigen. In one set of experiments, two ﬁrst trimester and two second
trimester placentas were processed by twomethods: half of the tissue
was dissociated using the usual enzymaticmethod (using collagenase I
and trypsin) and the other half was processed avoiding trypsin and
instead, using commercially available non-enzymatic dissociationAFig. 2.Hematopoietic progenitors were present in chorionic villi and the chorioamniotic mem
+6.5 weeks; B, 15.3 weeks) were stained with CD34, CD45 and PI and analyzed (see Fig. 1 l
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TRbuffer. The resulting cells were stained with anti-CD38 mAbs and
subjected to ﬂow cytometry. No notable change in the mean intensity
of CD38 expression or in the percentage of CD38+ cells was observed
between the two dissociationmethods. In a second set of experiments,
fetal liver tissue, which expresses high levels of CD38 and contains
abundant hematopoietic progenitors (Muench et al., 1994), was also
dissociated using enzymatic and non-enzymatic methods. As with the
results using placenta, no difference in CD38 expression by CD45+ cells
was observed (data not shown). Therefore, we conclude that the CD38
antigen is relatively resistant to digestion by trypsin and the lack of
CD38 expression by hematopoietic progenitors in the placenta is a
tissue-speciﬁc characteristic of these cells.
To investigate the fetal vs. maternal origin of the placental
hematopoietic progenitors, CD34++CD45low cells were sorted from a
placenta at 19 wk of gestation and fetal BM from the same male
specimen, as a fetal internal positive control. Slides were prepared
immediately after the cell puriﬁcation, and FISH experiments were
performed using X (green) and Y (red) chromosome-speciﬁc probes.
As shown in Fig. 1c, all the placental hematopoietic progenitors
displayed both X and Y ﬂuorescent chromosomes in the same manner
as the fetal BM cells, demonstrating their fetal origin. Results were
conﬁrmed by performing identical FISH analyses on total CD45+ cells
from ﬁrst and second trimester placentas.
Hematopoietic progenitors are present in chorionic villi and
fetal membranes
The ﬁnding of phenotypically identiﬁable hematopoietic progeni-
tors in chorionic villi throughout gestation, along with recent reports
of pluripotent stem cell markers in the amnion (Miki et al., 2007), led
us to explore the presence of hematopoietic progenitors in the
chorioamnioticmembranes. Fetalmembraneswere carefully dissected
from the villi of 7 placentas (6.3–15.3 wk), and both tissues were
analyzed by ﬂow cytometry (Fig. 2). Chorionic villi and fetal
membranes contained similar percentages of CD34++CD45low cells
and CD34+CD45low cells, indicating their broad distribution. The
number of CD34++CD45low cells isolated per gram of tissue from both
CT
EDbranes. Freshly isolated light-density cells fromvilli and fetal membranes (A, pooled 6.3
egend).
28 A. Bárcena et al. / Developmental Biology 327 (2009) 24–33regionswas also similar (data not shown). In preliminary experiments,
CD34++CD45low cells isolated fromboth the chorioamniotic membrane
and chorionic villi generated hematopoietic colonies in standard
methylcellulose cultures (data not shown), evidence that these two
extraembryonic sites are potentially hematopoietic. The CD45++ cells
lacking CD34 expression in both regions were primarily CD14+
Hofbauer cells (Fig. 5c).
The placenta is richer in hematopoietic progenitors in the embryonic
phase of development than in the fetal phase
Variation in the frequency of CD34++CD45low cells during gestation
(0.03–1.2%) was analyzed on a large set of 59 samples. Although theFig. 3. The hematopoietic compartment of the placenta changes during gestation. (a) Box
plot of total CD34++CD45 low placental cells grouped by gestational age (in weeks). (b)
Box plot of the number of CD34++CD45low cells per gram of tissue grouped by gestational
age. Box plots display the upper and lower quartiles surrounding the median (indicated
by the notch), and the span of the whiskers shows the range of the data. Diamonds
indicate the position of the mean values. Box width is proportional to sample size (5–
8 weeks, n=18; 9–12 weeks, n=15; 13–16 weeks, n=9; 17–20 weeks, n=7; 21–
24 weeks, n=7; 38–40 weeks, n=3). (c) Total numbers of CD34++CD45 low placental cells
(red squares) and CD34++CD45 low placental cells per gram (blue circles) of individual 5-
to 12-week tissues (n=30). Blue arrow indicates the high number of CD34++CD45 low
cells obtained per gram of 5-week tissues. Black arrow indicates the decrease at 9 weeks
in total numbers and cells/gram tissue of CD34++CD45 low cells. Red arrow indicates the
increase in total CD34++CD45 low placental cells at the end of the ﬁrst trimester.
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Atotal number of CD34++CD45low cells steadily increased as the
placenta grew (Fig. 3a), the highest numbers per gram of tissue
were recovered during the embryonic period (Fig. 3b). The frequency
of CD34++CD45low cells was about 7 times higher at 5–8 wk (n=18)
than at 9–12 wk (n=15); afterward, the values remained fairly
constant (Pb0.001; unpaired Mann–Whitney t-test). A plot of the
values from individual 5- to 12-wk placentas (n=33) showed that
tissue from the earliest gestational age analyzed (5 weeks) contained
the highest density of CD34++CD45low cells (Fig. 3c). Similar results
were obtained when the frequency of CD34+CD45low cells was
analyzed at different gestational ages (data not shown).
Immunolocalization of CD34+CD45+ cells in placenta
To identify and begin characterizing the placental hematopoietic
niche, we investigated the physical location of CD34+CD45+ cells using
both conventional immunoﬂuorescence (data not shown) and con-
focal microscopy (Fig. 4). We observed that cells co-expressing CD34
and CD45 antigens reside in primarily two locations: near placental
blood vessels of all sizes (Fig. 4D) and within the mesenchymal
compartment of the villous cores (Fig. 4E). The sensitivity of the
immunolocalization techniques did not allow us to distinguish
between CD34++ and CD34+ populations, which we can only detect
in quantitative manner using a ﬂuorescence-activated cell sorter
(FACS). The relatively low frequency of placental hematopoietic
progenitors (0.03–1.2%) that was predicted by ﬂow cytometric
analyses was conﬁrmed by confocal microscopy; we found 1–3
CD34+CD45+ cells per tissue section during 7 to 17 wk of gestation.
Regardless of their location, these cells were frequently found in close
contact with either endothelial CD34+CD45− cells (as shown in Figs. 4B
and D) or with vimentin-positive mesenchymal cells (Fig. 4E).
The placenta contains erythroid- and myeloid-committed progenitors
If placental hematopoiesis is an active process, we should ﬁnd
progenitors at various stages of differentiation and committed to several
lineages. These experiments focused mostly on the CD34+CD45low
population, which in other hematopoietic tissues such as the fetal liver
containsmaturinghematopoietic precursors ofmultiple lineage that can
be identiﬁed by lineage-speciﬁc antigens such as the erythroid markers
CD71, EpoR, and CD235a (glycophorin A) (Lammers et al., 2002; Olweus
et al., 1996). Active erythropoiesis was indicated by the abundance of
CD71andEpoRexpression inCD34+CD45lowcells (Fig. 5a).Manyof these
cells did not express the mature erythrocyte marker CD235a (glyco-
phorin A), suggesting that they were early erythroid precursors
(Lammers et al., 2002; Olweus et al.,1996). Therewas also an abundance
of CD235a+ cells that expressed EpoR and CD71 and variable levels of
CD34, suggesting the presence of intermediate-stage (CD34+) and late-
stage (CD34−) erythroid precursors in the placenta.
The presence of myeloid precursors among CD34+CD45low cells
was also investigated (Fig. 5b). Most CD34+ cells expressed CD13, and
5–30% of CD34+ cells expressed CD33. The most immature population
of CD34++CD45low cells also displayed low levels of these antigens, as
we have previously seen in fetal liver (Muench et al., 1994). We
observed the broad expression of CD13 by placental cells of
hematopoietic and nonhematopoietic origin. CD13 is a membrane-
bound aminopeptidase that is expressed by endometrial and decidual
tissues (Imai et al., 1992). Four-color FACS results indicated that about
half of the CD13+ cells displayed CD33 and CD14 (Fig. 5c), consistent
with amyeloid origin. The remaining CD13+CD33−CD14− cells, possibly
mesenchymal, were nonhematopoietic, since they lacked CD45
expression (data not shown). The CD14 expression on CD13+CD33+
cells correlates with the loss of CD34 (data not shown), indicating that
they are mature myeloid cells. CD14+ cells are specialized resident
macrophages (Hofbauer cells) in the chorionic villi, present from
4 week of gestation until term (Benischke and Kaufmann, 2000) and
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Fig. 4. Localization andmorphology of CD34+CD45+ cells within the human placenta. (A) Chorionic villi biopsied from a 9-week human placenta embedded in gelatin to demonstrate
the macroscopic anatomy of these structures (2× magniﬁcation). fs, fetal side; fm, fetal membranes; v, villus; ms, maternal side. (B) CD34+CD45+ cell within the villous mesenchyme
in close contact with a CD34+CD45− endothelial cell. Tissue sections of the chorionic villi at the gestational ages indicated were stained with anti-CD34 (green) and anti-CD45 (red)
mAbs, along with TOTO-3 iodide (blue). Confocal images were obtained by sequential scanning at 63× magniﬁcation. (C) Orthogonal views of two CD34+CD45+ cells, stained as in
panel B and from the same 17-week placenta, demonstrating their close associations with CD34+CD45− cells. The Z projection (inset) shows the large size and complexmorphology of
the putative progenitors' nuclei. (D) Longitudinal section of a villus showing a single CD34+CD45+ cell surrounded by a cluster of CD34+ CD45− cells. s, syncytium. The tissue section
was stained with anti-CD34 (green), anti-CD45 (red), and anti-vimentin (purple) mAbs, Hoescht (blue), and visualized with differential interference contrast (DIC, gray scale). (E)
Section of a young villus near the fetal membranes with CD34+CD45+ cells in the center (stained as in panel D). The Z projection (inset) demonstrates a cluster of CD34+CD45+ cells
that appeared to be tethered to their vimentin-positive neighbors.
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EDthey constitute the ﬁrst mature and most abundant leukocyte
population in the placenta. Hofbauer cells (Fig. 5c) expressed high
levels of VEGF-R2 and Tie2 (angiopoietin receptor) (Demir et al., 2004;
Kayisli et al., 2006) and low levels of CD86; one-third coexpressed the
myeloid marker CD15. Most Hofbauer cells expressed low levels of
CD80, CD83, DC-SIGN, CD11a, CD11b, and CD11c andmoderate to high
levels of HLA-DR (data not shown), indicating a mixture of markers
expressed on dendritic cells and macrophages.
The presence of other leukocyte subsets in the placenta was
investigated by examining the expression of CD3 (displayed by T
lymphocytes) and CD56, a marker of natural killer (NK) cells. In
cells isolated from a placenta at 22 weeks of gestation (Fig. 5d), the
CD45+ population contained no detectable T lymphocytes and very
few NK cells. The lack of T cells was consistently observed (n=7;
12.5–39.5 weeks), and the number of NK cells ranged from 0.05 to
3.5% (n=9; 10–39.5 weeks). From our data we conclude that most
of the mature hematopoietic cells expressing high levels of CD45 in
the human placenta are Hofbauer cells and that very few NK cells
are present.
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We used the presence of mature lymphocyte populations in our
placental preparations as an indicator of the level of blood
contamination, since blood is a source of circulating hematopoietic
precursors. In preliminary studies, we determined that extensive
washes of placental tissue prior to its enzymatic digestionwere critical
in removing blood contamination. Flow cytometric analyses of the
cells recovered from the washes showed the presence of T and NK
lymphocytes at the frequencies expected in fetal blood (Muench et al.,
2001). Moreover, the presence of hematopoietic precursors within the
placental tissuewas further conﬁrmed by confocal microscopy (Fig. 4).
CD34++CD45low cells were identiﬁed within the mesenchymal cores of
villi, sometimes associated with endothelial cells, but these cells were
not observed in the intravascular spaces.
CD34++CD45low and CD34+CD45low placental cells possess multilineage
hematopoietic potential
In vitro clonogenic hematopoietic progenitor assays carried out
with sorted CD34++CD45low and CD34+CD45low cells indicated that
Fig. 5. Erythroid andmyeloid progenitors together with NK cells were present in the placenta throughout gestation. (a) A freshly isolated light-density cell suspension from a 21-week
placenta was stained for erythroid markers and analyzed (see Fig. 1 legend). Red indicates cells stained with an anti-CD235a-FITC (glycophorin A) mAb. (b) Analysis of a 12-week
light-density placental cell suspension using mAbs that recognized myeloid progenitors in combination with an anti-CD34 mAb. (c) Four-color analysis of antigen expression on
mature myeloid CD14+ cells (purple) (same cells as in panel b). (d) Analysis of CD3 and CD56 expression on 22-week placental cells. In all experiments, 1–2×105 PI− cells were
analyzed. Results are representative of 5 experiments.
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(CFU-GM), with a small number of mixed lineage colonies containing
both myeloid and erythroid cells (Fig. 6a). No pure burst-forming
unit–erythroid (BFU-E) colonies were observed (n=7). Lineage
composition of the colonies was examined morphologically and by
FACS of individually plucked colonies stained with mAbs against
CD45, CD14 and CD15 (data not shown). Our results showed that
both CD34++CD45low and CD34+CD45low placental cells are multi-
potent hematopoietic progenitors that generated both myeloid and
erythroid colonies.
The survival and growth of HSCs and progenitors is regulated by
cytokines and other environmental factors. Hematopoietic precursors
respond differently to these growth regulators at different stages of
human ontogeny. To begin to understand if placental hematopoietic
precursors are similarly regulated as other fetal hematopoietic cells,
we ﬁrst investigated the serum dependency of CD34++CD45low cells
(Fig. 6b). Serum did not signiﬁcantly affect the production of CFU-
mix colonies. The generation of CFU-GM colonies was higher when
serum was added to serum-deprived medium (SDM), but still lower
than that in Methocult GF H4435, which has a very high serum
content (30%). Similar results were obtained with three different
batches of FBS from two different companies; all were able to support
the in vitro growth and differentiation of sorted CD34++CD45low cells
from umbilical cord blood (UCB), indicating that placental hemato-
poietic precursors have growth requirements different from those of
similar populations of cells isolated from fetal liver (Golﬁer et al.,
1999) and UCB.
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TR The multipotency of placental CD34++CD45low cells was alsofurther investigated in liquid cultures (Muench and Bárcena, 2001;Muench et al., 2000). Freshly isolated CD34++CD45low cells did notexpress lymphoid cell surface markers, such as CD19, CD20, sIgM orCD56 (data not shown). Sorted progenitors from 3 individualplacentas ranging from 12 to 19 weeks of gestation generated 1–6%CD56+ NK cells that coexpressed CD45 (data not shown) in 21-day
cultures supported by lymphoid-permissive deﬁned culture condi-
tions (in the absence of serum and stroma and in the presence of
a cocktail of recombinant cytokines) and a minor population of
CD10+CD19+ cells (0.2–0.8%), indicating B-cell differentiation (Fig.
7a). These cells were CD20− or surface-bound IgM− (data not shown),
suggesting that they were pre-B cells that had not fully matured.
Cultured CD34++CD45low cells also generated megakaryocytes,
erythrocytes and myeloid cells when cultured for 3 weeks in
deﬁned myelo-erythroid-permissive conditions (Fig. 7b) (Bárcena et
al., 1999; Muench and Bárcena, 2001). CD41 is a member of the
integrin family expressed by megakaryocytes and platelets (Duper-
ray et al., 1989). As shown in Fig. 1, freshly isolated CD34++CD45low
cells were CD41−, which was acquired by 2–7% of their progeny.
Differentiation of CD34++CD45low cells along the erythroid lineage
was indicated by expression of CD235a on 50–75% of their progeny.
Complete monocytic differentiation was indicated by 1–15% of CD14
on CD33+ cells.
To fully support the differentiation of placental CD34++CD45low
cells into B cells, co-culture with the murine stromal cell line
MS-5 was performed as previously described (De Smedt et al., 2002).
Fig. 6. Colony-forming activity of placental hematopoietic progenitors. (a) Sorted
populations from the placentas at the indicated gestational ages were plated in
Methocult and scored at 3.5 weeks of culture. Results are shown as themean±SEM of 8–
11 replicates for 4 experiments. CFU-GM, myeloid colonies. CFU-Mix, colonies
containing both myeloid and erythroid cells. (b) Effects of FBS on colony-forming
activity of CD34++CD45low sorted cells from a 19-week placenta. Cells were grown in
commercial Methocult or in SDM supplemented with FBS.
Fig. 7. CD34++CD45+ placental cells have multilineage hematopoietic potential.
CD34++CD45low cells sorted from a 19-week placenta were cultured at 7.5×103 cells/
well in 48-well plates in SDM supplemented with SCF+FL+IL-7+ IL-15+GM-CSF+ IL-3
(a) or SCF+FL+Epo+GM-CSF+TPO (b). Viable cells (5×104) were analyzed after
23 days in culture (see Fig. 1 legend). Results are representative of 3 experiments. (c)
CD34++CD45low cells sorted from a 12-week placenta were cultured at 5×104 cells/
well in 48-well plates with MS-5 murine BM stromal cells as feeders. After 3 weeks in
culture, cells were detached, washed and stained with the indicated mAbs. The
results of an analysis using a gate that contained viable CD45+FITC cells (left) and
CD45+PE cells (right) are shown.
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pically characterized. As shown in Fig. 7c, most of the progeny of
CD34++CD45low cells were fully differentiated B cells expressing
CD19, CD20 and surface IgM.
Discussion
We report that as early as 5 wk of gestation the human placenta
contains hematopoietic progenitors at various stages of development,
including multipotent and lineage-committed cells, demonstrating
that there is ongoing erythropoiesis and myelopoiesis in the human
placenta. Thus, it appears that this organ adds to the output of other
embryonic and fetal hematopoietic sources, such as the AGM and the
liver. The density of these cells sharply declines at the commencement
of the fetal phase of development, likely because other fetal sites begin
to function as hematopoietic tissues.
Placental hematopoietic progenitors share some phenotypic
characteristics with their counterparts in the AGM, fetal liver, and
fetal BM (Muench et al., 1994; Tavian et al., 1996, 1999), but they also
display unique phenotypic features. CD34++CD45low cells from ﬁrst
and second trimester placentas expressed CD133, CD90, CD117, CD33,
and HLA-DR. However, placental progenitors, regardless of gestational
age, were largely CD38−, a characteristic of the very scarce population
of HSCs. This is in contrast to the majority of progenitors in fetal,
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al., 1993; Muench et al., 1994; Terstappen et al., 1991). The absence of
CD38 expression was not due to enzymatic digestion; placental
populations that were obtained enzymatically (dissociated with
trypsin) or nonenzymatically (dissociated with commercial cell
dissociation buffers) yielded hematopoietic cells that lacked CD38
(data not shown). Our data provide evidence for placental cells with
many of the phenotypic characteristics of fetal HSCs but with some
variability in expression levels of stem cell markers is apparent.
The lack of CD38 expression by placental hematopoietic progeni-
tors could be due to tissue-speciﬁc regulation of CD38 gene
expression. CD38 was detected on only ∼25% of CD45+ mature cells
isolated from second trimester placentas, highlighting the observation
that this organ contains cells that have an unusual phenotype. We
previously reported that the in vitro expression of CD38 by
hematopoietic progenitors sorted from fetal liver is dependent on
all-trans-retinoic acid (ATRA) and 9-cis-retinoic acid (Muench et al.,
1999), cellular products derived from retinol (vitamin A) metabolism
that are found in serum. Retinoids are potent regulators of
hematopoiesis, inhibiting growth of early progenitors and enhancing
differentiation at many points in the pathway (Tocci et al., 1996; van
Bockstaele et al., 1993). We hypothesize that the lack of CD38
expression by human placenta-derived cells is a consequence ofED
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embryonic/fetal exposure to ATRA. For instance, maternal retinol-
binding protein does not cross the placenta and is not synthesized by
embryonic/fetal tissues. Therefore, it is likely that the delivery and
maintenance of vitamin A at levels that are required for normal
development is controlled by a less efﬁcient mechanism, such as
retinol binding to lipoproteins (Quadro et al., 2004).
Fetal liver hematopoietic progenitors produce higher numbers of
CFU-C and expand more vigorously in liquid cultures when grown in
SDM than in medium supplemented with FBS (Golﬁer et al., 2000).
The growth of placental CD34++CD45low cells, however, was highly
serum dependent. Another potentially signiﬁcant functional differ-
ence between fetal liver and placental hematopoietic progenitors is
that neither CD34++CD45low nor CD34+CD45low cells isolated from ﬁrst
or second trimester placentas produced BFU-E in standard methyl-
cellulose cultures that support the generation of erythroid colonies,
but placental precursors were capable of vigorous erythropoiesis in
liquid cultures. These ﬁndings suggest that placental hematopoietic
precursors are functionally different from their fetal liver or BM
counterparts. Alternatively, the placental hematopoietic niche might
be unique when compared with other intra-embryonic and intra-fetal
hematopoietic environments. The uniqueness of the placental
environment could have lasting effects on the growth properties of
resident HSCs and progenitors, as these cells do not respond to growth
signals in culture in the same way as fetal liver or BM cells. In addition
to the unique nature of the hematopoietic niche provided by the
placenta, multiparametric (6–7 colors) analyses of ﬁrst and second
trimester placentas have highlighted the considerable heterogeneity
of CD34++CD45low and CD34+CD45low placental cells. This ﬁnding
suggests that, in addition to multipotent hematopoietic progenitors,
these populations could contain several other kinds of progenitors and
mature cells (A.B., M.O.M., M.K. and S.J.F., manuscript in preparation),
which might partially account for their lower clonogenecity.
One essential characteristic of primitive, pluripotent hematopoie-
tic progenitors and HSCs is their ability to generate cells that
contribute to all the blood lineages. This is particularly pivotal for
our study, since it is not known if human placental progenitors are
embryonic (with exclusive myelo-erythroid potential) or if they are
capable of establishing deﬁnitive hematopoiesis (myelo-erythroid and
lymphoid potential). Our data show that CD34++CD45low placental
cells generate multilineage progeny, including lymphoid CD56+ and
CD10+CD19+ cells under deﬁned culture conditions, and fullymature B
cells expressing surface IgM in co-culture with the MS-5 cell line.
These data indicate that human placental progenitors can be
categorized as deﬁnitive progenitors. While we have evidence of the
myeloid-erythroid potential of CD34+CD45low cells, their lymphoid
potential is still under investigation.
Since the intrinsic vasculature of the human placenta develops at a
very early stage—∼3 weeks of gestation (Hamilton and Boyd, 1970)—it
is extremely difﬁcult to determine whether the multipotent progeni-
tors and putative HSCs found in the placenta emerge in situ or
immigrate via the fetal circulation. The dearth of T and NK cells in the
placental isolates indicates that careful dissection and washing of the
chorionic villi prevented contamination with fetal or maternal blood,
since these lymphocyte populations are readily detected in fetal blood
by 9 weeks (Muench et al., 2001). Our immunolocalization studies
show that small numbers of CD34++CD45+ cells reside in several areas
of the chorionic villi, within mesenchymal cores and in association
with the vasculature. Reports that the mouse placenta is hematopoie-
tic before vascularization and fusion of the allantois to the chorion
(Corbel et al., 2007; Zeigler et al., 2006), and that the placenta
produces HSCs in the absence of circulation in Ncx1 knockout mice
whose hearts fail to beat (Rhodes et al., 2008), support the theory that
the placenta is not only a niche but also a source of hematopoietic
cells. However, the relative importance of the contribution from this
site—timing and numbers of cells generated—is not known. The
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liver, occurs simultaneously with the AGM, and peaks around mid
gestation (Alvarez-Silva et al., 2003). Although the placental con-
tribution to the fetal HSC pool is transient, the HSC output of the
placenta is thought to be 15-fold higher than that of the AGM (Gekas
et al., 2005). It is thus possible that the placenta contributes more cells
than the AGM to the colonization of the liver rudiment.
Another important question is why the placenta is involved in
hematopoiesis. We speculate that the large size of the placenta relative
to the embryo during early gestation might provide a convenient
hematopoietic niche at time in development when there is a great need
for hematopoietic activity to supply expanding circulatory system.
Placental hematopoiesis could also generate erythrocytes near the site
where oxygen is transported by trophoblasts from maternal blood.
There may also be immunological and physiological reasons for this
layout: the early in situ production of the specialized placental
macrophages (Hofbauer cells) that populate the mesenchymal cores of
the chorionic villi could help protect the embryo/fetus from microbial
infections while training the developing immune cells to recognize a
subset of the pathogens that will be encountered later in life.
To our knowledge, this is the ﬁrst report providing evidence of
hematopoiesis in the humanplacenta that raises interestingpossibilities
about the potential clinical utility of placentas—which are routinely
discarded after terminations early in pregnancy or live births—as a
possible source of additional human progenitors with hematopoietic
(and nonhematopoietic) potential. Further functional studies are
required to better deﬁne the placental hematopoietic niche, its role in
the embryo/fetus as a source of HSCs, and the full capabilities of
placental hematopoietic progenitors as discerned by long-term growth
and engraftment assays
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Note added in proof
Following acceptance of this article for publication, we showed
that CD34++CD45low cells isolated from midgestation human placen-
tas and transplanted into immunodeﬁcient mice (NOD/SCID) recon-
stituted erythroid, myeloid, lymphoid and progenitor cells after 11
weeks, while CD34+CD45low cells did not reconstitute, further
evincing the presence of hematopoietic stem cells in this organ.
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